Jay S. Stout - 17 Apr 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Technology Officer
Signature: /s/ Eva Renee Barnett, attorney-in-fact for Jay S. Stout
Issuer symbol: IMVT
Transactions as of: 17 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 19 Apr 2023, 16:23:19 UTC
Next filing: 04 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Award	$0	+100,000		$0.000000	100,000	17 Apr 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMVT	Stock Option (right to buy)	Award	$0	+150,000		$0.000000	150,000	17 Apr 2023	Common Stock	150,000	$15.47	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units awards ("RSUs").
F2	The RSUs vest over four years, with 25% of the RSUs vesting on April 17, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3	Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 17, 2024 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.